Printer Friendly

MEDCO RESEARCH NAMES DIRECTOR, RADIOPHARMACEUTICAL CLINICAL RESEARCH

 LOS ANGELES, July 14 /PRNewswire/ -- Medco Research, Inc. (AMEX: MRE) announced today that Cesare Orlandi, M.D., has joined the company as director - radiopharmaceutical clinical research. Dr. Orlandi comes to Medco from The Du Pont Merck Pharmaceutical Company, radiopharmaceutical division where he has been involved since 1988 in the development of radio-pharmaceutical cardiac imaging agents, including IV Persantine(R) and Cardiolite(R).
 Dr. Orlandi will direct Medco's clinical development program for IPPA. IPPA is a radiolabeled substance under development by Medco for detection of viable cardiac tissue in patients who are being considered for coronary bypass surgery or angioplasty to improve blood supply to the heart.
 A Phase II clinical trial with IPPA has been completed and results are currently being analyzed to evaluate the clinical diagnostic utility of this agent. Pending a successful outcome of this analysis and discussions of the results with the FDA, Medco plans to initiate a multicenter Phase III clinical trial in the fourth quarter of this year.
 Prior to joining Du Pont Merck, Dr. Orlandi, age 43, completed a research fellowship in clinical radiology at Harvard Medical School and Brigham and Women's Hospital; he also served as staff physician in internal medicine at the University of Pavia Medical School in Italy.
 Dr. Archie Prestayko, Medco's president and chief executive officer, said, "We are very pleased to have Dr. Orlandi join us as we relocate Medco headquarters to the Research Triangle Park in North Carolina early next month. He brings significant experience in radiopharmaceuticals to our research and development programs."
 IPPA is the second product (the first is Adenoscan(R)) that Medco is developing for use in nuclear cardiology diagnostics.
 Medco Research, Inc. is a pharmaceutical company engaged in the acquisition, research and development of new prescription drugs for the diagnosis or treatment of certain cardiovascular diseases and cancer.
 -0- 7/14/93
 /CONTACT: James F. Mohar of Medco Research, Inc., 213-966-4148, or Fredric J. Spar of Kekst and Company, 212-593-2655, for Medco Research/
 (MRE)


CO: Medco Research, Inc. ST: California IN: MTC SU: PER

MP -- NY034 -- 1301 07/14/93 10:33 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 14, 1993
Words:349
Previous Article:MAGNA-LAB REPORTS FIRST QUARTER RESULTS
Next Article:MOUNTAINEER BANKSHARES OF W.VA., INC. REPORTS INCREASED SECOND QUARTER EARNINGS
Topics:


Related Articles
MEDCO RESEARCH NAMES HEALTH CARE EXECUTIVE TO BOARD OF DIRECTORS; WILLIAM M. BARTLETT TO ALSO SERVE AS CONSULTANT
MEDCO RESEARCH ELECTS RICHARD C. WILLIAMS CHAIRMAN
MEDCO RESEARCH ANNOUNCES APPOINTMENT OF EUGENE STEP TO BOARD OF DIRECTORS
MEDCO RESEARCH NAMES CHIEF FINANCIAL OFFICER
MEDCO RESEARCH APPOINTS ROGER BLEVINS CHIEF OPERATING OFFICER
MEDCO RESEARCH APPOINTS ANNE MCKAY DIRECTOR OF REGULATORY AFFAIRS
MEDCO RESEARCH APPOINTS ROGER BLEVINS PRESIDENT
MEDCO RESEARCH PROMOTES TWO MEMBERS OF MANAGEMENT TEAM
MEDCO RESEARCH ELECTS MANFRED MOSK TO BOARD OF DIRECTORS
MEDCO RESEARCH ANNOUNCES APPOINTMENTS TO THE BOARD OF DIRECTORS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters